Mechanism of action
Capsaicin is a selective agonist of the transient receptor potential vanilloid 1 (TRPV1) channel, a nonselective cation channel expressed on nociceptive sensory neurons, particularly unmyelinated C-fibers and thinly myelinated Aδ-fibers.
Upon initial application, capsaicin activates TRPV1 channels, causing calcium influx into the nerve terminal. This triggers the release of substance P and other neuropeptides such as calcitonin gene-related peptide (CGRP) from peripheral nerve endings, producing an immediate burning or stinging sensation.
With repeated or high-concentration exposure, capsaicin produces a paradoxical analgesic effect through several mechanisms:
- Substance P depletion: Continuous stimulation exhausts presynaptic stores of substance P faster than the neuron can synthesize it, reducing pain signal transmission to the spinal cord.
- Nociceptor defunctionalization: Prolonged TRPV1 activation leads to reversible degeneration of epidermal nerve fiber terminals, reducing the density of functional nociceptors in the treated area.
- Receptor desensitization: TRPV1 channels become refractory to further activation.
- Altered gene expression: Chronic exposure downregulates TRPV1 expression and modifies the phenotype of sensory neurons.
The net effect is a reduction in pain perception from the treated area. The analgesic effect persists for weeks to months after treatment cessation, as nerve terminals gradually regenerate. High-concentration patches (8%) can produce prolonged analgesia from a single application, while low-concentration formulations (0.025-0.1%) require repeated daily application to achieve and maintain therapeutic effect.
- Capsaicin is a TRPV1 agonist that paradoxically relieves pain by depleting substance P and defunctionalizing nociceptive nerve terminals
- Initial burning sensation is expected and results from substance P release; analgesia develops only after repeated applications as substance P is depleted
- First-line topical therapy for postherpetic neuralgia, especially when oral agents like gabapentin are ineffective or contraindicated
- High-concentration (8%) patches provide up to 12 weeks of analgesia from a single in-office application; low-concentration creams (0.025-0.1%) require daily use
- Negligible systemic absorption makes capsaicin safe in patients on multiple medications or with comorbidities precluding oral analgesics
- Do not apply to broken skin, and avoid heat exposure after application as both intensify burning and increase risk of skin injury
- Thoroughly wash hands after application to prevent accidental ocular or mucous membrane contact, which causes severe irritation
- Transient hypertension can occur during high-concentration patch application; monitor blood pressure in susceptible patients
Indications
Capsaicin is approved for topical treatment of various pain conditions:
Neuropathic pain syndromes
- Postherpetic neuralgia: Most well-established indication, particularly with high-concentration (8%) patches
- Diabetic peripheral neuropathy: For symptomatic relief of painful diabetic neuropathy
- HIV-associated neuropathy: Adjunctive treatment for HIV-related distal sensory polyneuropathy
Musculoskeletal pain
- Osteoarthritis: Particularly knee and hand osteoarthritis, used as adjunct to oral analgesics
- Chronic musculoskeletal pain: Various regional pain syndromes
Other pain conditions
- Post-surgical neuropathic pain: Including post-mastectomy pain and post-amputation stump pain
- Complex regional pain syndrome: As part of multimodal pain management
- Chronic pruritus: Off-label use for localized itching, including brachioradial pruritus and notalgia paresthetica
Capsaicin is typically considered when first-line systemic analgesics are ineffective, contraindicated, or produce intolerable side effects. It is particularly useful for localized pain syndromes where systemic drug exposure can be minimized. The high-concentration patch formulation is administered in clinical settings, while low-concentration creams and lotions are available over-the-counter for self-application.
Pharmacokinetics
Capsaicin exhibits minimal systemic absorption following topical application, which contributes to its favorable safety profile.
Absorption: Capsaicin penetrates the stratum corneum to reach dermal nerve endings. Systemic absorption is negligible even with high-concentration patches applied to large surface areas. Plasma levels, when detectable, are extremely low and transient.
Distribution: The drug acts locally at the site of application. Due to minimal systemic absorption, tissue distribution beyond the application site is not clinically relevant.
Metabolism: Any systemically absorbed capsaicin undergoes hepatic metabolism, primarily via cytochrome P450 enzymes, but the quantities are too small to produce active metabolites at therapeutic concentrations.
Elimination: Metabolites are excreted in urine. The elimination half-life of any absorbed capsaicin is short, but this parameter has limited clinical significance given the local mechanism of action.
Duration of effect: The pharmacodynamic effect (analgesia) significantly outlasts any systemic presence of the drug. After application of high-concentration (8%) patches, pain relief can persist for 12 weeks or longer, despite complete clearance of capsaicin from plasma within hours. This prolonged effect reflects the time required for regeneration of defunctionalized nerve terminals.
Low-concentration formulations (0.025-0.1% creams) require application 3-4 times daily for several weeks before maximal analgesic effect is achieved. The initial burning sensation typically diminishes after the first week of regular use as desensitization occurs.
Adverse effects
Capsaicin is generally well-tolerated with predominantly local effects. Systemic adverse effects are rare due to negligible absorption.
Local reactions (very common)
- Burning, stinging, erythema: Occur in the majority of patients, especially during initial applications. Usually diminish with continued use.
- Pain at application site: Transient worsening of pain is expected in the first few days.
- Pruritus: Itching at the application site
- Papular rash: May develop in sensitive individuals
- Skin dryness: With prolonged use
Application-related complications
- Cough and respiratory irritation: If capsaicin becomes aerosolized or if patients touch their face after application without washing hands
- Ocular irritation: Severe burning if capsaicin contacts eyes; requires immediate irrigation
- Sneezing, lacrimation: From airborne particles during application
With high-concentration patches
- Transient hypertension: Blood pressure elevation may occur during or immediately after application, likely due to pain from initial TRPV1 activation
- Vasovagal reactions: Rare, but can include syncope during application
- Skin injury: Erythema, edema, and papules are common; rarely, second-degree burns or blistering may occur if skin is damaged before application or if improper technique is used
Systemic effects (rare) Given minimal absorption, systemic toxicity is extremely uncommon with proper use. Accidental ingestion (not therapeutic use) can cause gastrointestinal distress.
Management of adverse effects: Local burning can be mitigated by cooling the area, applying topical local anesthetics before capsaicin (particularly with high-concentration patches), or using oral analgesics during the initial treatment period. If ocular exposure occurs, copious irrigation with cool water is essential. Affected skin should not be exposed to heat sources, as this can intensify burning sensation.
Contraindications and warnings
Absolute contraindications
- Hypersensitivity: Known allergy to capsaicin or chili peppers
- Broken or irritated skin: Application to damaged skin increases absorption and risk of adverse effects
Relative contraindications and warnings
Skin integrity: Do not apply to wounds, damaged skin, or areas with active dermatitis. For high-concentration patches, skin must be intact and dry.
Pregnancy and lactation: Capsaicin is Pregnancy Category Unknown (not formally assigned under old FDA system; not evaluated under new PLLR system). Systemic exposure is negligible, suggesting low risk, but safety data are limited. Use during pregnancy only if clearly needed. It is unknown whether capsaicin is excreted in breast milk, but given minimal systemic absorption, risk to nursing infants is likely minimal.
Pediatric use: Safety and efficacy in children under 18 years have not been established for prescription formulations. Low-concentration over-the-counter products are sometimes used in adolescents, but evidence is limited.
Cardiovascular considerations: Transient blood pressure increases can occur with high-concentration patch application. Monitor patients with unstable or poorly controlled hypertension.
Application precautions
- Hand washing: Thoroughly wash hands immediately after application unless treating hands themselves. Wear gloves if applying to another person.
- Avoid heat exposure: Do not apply heat to treated areas for several hours after application, as this intensifies burning.
- Mucous membrane contact: Avoid contact with eyes, mouth, genitals, and other mucous membranes. If contact occurs, irrigate immediately with water (not oil-based substances, which can spread capsaicin).
- Bathing: Do not bathe or shower immediately before or after application (particularly with high-concentration patches), as this can alter skin barrier function.
Drug application technique: High-concentration (8%) patches should be applied only by healthcare professionals in controlled settings where topical anesthetics can be used and adverse reactions can be managed. Patients receiving high-concentration treatment should be monitored for at least 60 minutes post-application.
Drug interactions
Capsaicin has minimal systemic absorption, resulting in very few clinically significant drug interactions.
Topical interactions
Topical local anesthetics: Often used concurrently before high-concentration capsaicin patch application to reduce initial burning pain. Lidocaine or other local anesthetics do not interfere with capsaicin's mechanism and are routinely used in clinical practice to improve tolerability.
Other topical preparations: Avoid simultaneous application of other topical medications to the same skin area, as absorption characteristics of either agent may be altered. Separate applications by several hours.
Theoretical interactions
Because capsaicin acts via TRPV1 receptors and depletes substance P, there are theoretical considerations regarding drugs that affect these pathways:
ACE inhibitors: Substance P is thought to contribute to ACE inhibitor-induced cough. Some studies have explored capsaicin as treatment for this adverse effect, but no clinically significant interaction has been established with topical capsaicin use.
Anticoagulants: No direct interaction, but patients on anticoagulants who develop skin injury from capsaicin application may have prolonged bleeding. Use with standard precautions.
Antihypertensives: Transient blood pressure elevation during high-concentration patch application is not typically a problem for patients on stable antihypertensive regimens, but monitoring is prudent in those with poorly controlled hypertension.
Smoking: Chronic cigarette smoking may reduce capsaicin efficacy by altering TRPV1 expression, though this is based on limited data and is not a formal contraindication.
Alcohol on skin: Avoid applying alcohol-based products to the treatment area, as alcohol can increase capsaicin absorption and intensify burning.
Overall, capsaicin's interaction profile is favorable compared to systemic analgesics, making it a useful option for patients on multiple medications.
Clinical pearls
Biphasic effect: The hallmark of capsaicin therapy is initial excitation (burning) followed by prolonged inhibition (analgesia). Warn patients that temporary worsening of symptoms is expected and does not indicate treatment failure.
Patient counseling for adherence: With low-concentration formulations, many patients discontinue treatment during the first week due to burning. Emphasize that analgesia develops only after 1-2 weeks of regular use. Consider starting with lower concentrations (0.025%) before advancing to 0.075-0.1%.
High- vs low-concentration formulations: High-concentration (8%) patches provide prolonged relief (up to 12 weeks) from a single application but require in-office administration. Low-concentration creams (0.025-0.1%) are self-administered but require daily application and have delayed onset of benefit. Choose based on patient compliance, access to care, and pain severity.
Delineating treatment area: For high-concentration patches, mark painful areas before applying topical anesthetic, as the anesthetic will mask the painful region. This ensures accurate patch placement.
Substance P depletion and diagnosis: Capsaicin pre-treatment can be used diagnostically to identify substance P-mediated conditions. It has been used in research to study neurogenic inflammation.
Combination therapy: Capsaicin is most effective as part of multimodal analgesia. It does not preclude use of oral analgesics, gabapentinoids, or other neuropathic pain medications. The localized mechanism allows reduction of systemic medication doses.
Mechanism recall: Remember TRPV1 is a heat and pain sensor ("vanilloid receptor"). Capsaicin is the molecule in chili peppers that makes them "hot." This same heat-sensing mechanism is exploited therapeutically.
Not a counterirritant: Unlike menthol or methyl salicylate (which produce cooling/heating sensations that mask pain), capsaicin causes actual neurochemical changes in nociceptors. It is disease-modifying at the local level, not merely symptom-masking.
Exam associations: Postherpetic neuralgia and capsaicin are classically paired in exam questions. If a patient has failed oral gabapentin or pregabalin for PHN, capsaicin is a high-yield next step, especially if pain is localized.
Incomplete responders: Approximately 30-40% of patients do not achieve adequate analgesia with capsaicin. If no benefit after 4-6 weeks of regular use (low-concentration) or 12 weeks (high-concentration), consider alternative therapies.
HOT PEPPERS for capsaicin mechanism: Heat receptor (TRPV1), Overkill causes defunctionalization, Transient burning then analgesia, Postherpetic neuralgia indication, Epidermal nerve fiber loss, Pain from Pepper molecule, Exhausts substance P stores, Repeated use required (low-concentration), Skin must be intact
Practice questions
1. A 68-year-old woman with diabetes presents with burning pain in both feet that worsens at night. She has tried gabapentin with minimal relief and cannot tolerate higher doses due to sedation. Physical examination shows decreased sensation to light touch and pinprick in a stocking distribution. Which of the following best describes the mechanism of action of topical capsaicin, an appropriate next treatment option?
2. A 72-year-old man develops severe burning pain along the right T6 dermatome three weeks after a vesicular rash in the same distribution has healed. Oral gabapentin 900 mg three times daily provides inadequate relief. The patient has a history of heart failure and chronic kidney disease. A high-concentration capsaicin patch is applied in the clinic after topical lidocaine pre-treatment. Thirty minutes after patch application, which of the following findings is most likely?
3. A 45-year-old woman with painful diabetic neuropathy begins using capsaicin 0.075% cream four times daily as directed. After three days, she calls the clinic reporting that her foot pain has worsened and she is experiencing significant burning at the application sites. She asks whether she should discontinue the medication. Which of the following is the most appropriate response?
Frequently asked questions
How does capsaicin work for pain relief?
Capsaicin binds to TRPV1 receptors on pain-sensing nerve fibers, initially causing burning by releasing substance P, but with continued use it depletes substance P stores and causes nerve terminals to become temporarily non-functional (defunctionalized). This results in long-lasting pain relief in the treated area. The paradoxical effect—initial pain followed by analgesia—is the key to its mechanism.
What are the side effects of capsaicin cream?
The most common side effect is burning, stinging, or pain at the application site, especially during the first week of use. This typically decreases with continued application. Other local effects include redness, itching, and dry skin. If capsaicin contacts the eyes or mucous membranes, it causes intense burning and requires immediate water irrigation. Systemic side effects are rare because capsaicin is barely absorbed through intact skin.
How long does it take for capsaicin to work?
The timeline depends on the formulation. Low-concentration creams (0.025-0.1%) require daily application for 1-2 weeks before noticeable pain relief begins, with maximal effect at 4-6 weeks. High-concentration (8%) patches can provide pain relief within days, lasting up to 12 weeks from a single application. Initial burning is immediate but typically lessens within the first week of regular use.
What is capsaicin cream used to treat?
Capsaicin is primarily used for neuropathic pain conditions, especially postherpetic neuralgia (nerve pain after shingles) and diabetic peripheral neuropathy. It is also used for osteoarthritis pain, particularly in the knees and hands, and for other chronic pain syndromes including HIV-associated neuropathy and post-surgical nerve pain. It works best for localized pain areas where topical application is practical.
Capsaicin vs lidocaine — what is the difference?
Capsaicin and lidocaine are both topical analgesics but work by completely different mechanisms. Lidocaine is a local anesthetic that blocks sodium channels to prevent nerve signal transmission, providing immediate but temporary relief (hours). Capsaicin is a TRPV1 agonist that depletes substance P and defunctionalizes nerve endings, causing delayed but long-lasting analgesia (weeks to months). Lidocaine is often used before capsaicin application to reduce initial burning. Capsaicin is preferred for chronic neuropathic pain, while lidocaine suits acute or procedural pain.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: M02AB01WHO ATC/DDD index: N01BX04
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.